MLL1 Antibody (C-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP6182a
Background:
Chromosome 11q23 translocations targeting mixed-lineage leukemia 1 (MLL) gene have been correlated with human acute leukemias, including lymphoid, myeloid, monoblastic and myelomonocytic varieties. More than 3 dozen genes that fuse to with MLL have been identified in various types of malignancies, including AF4, AF9, ENL, CBL, LARG, LPP, GMPS, and FBP17. The 431 kDa MLL protein exhibits greatest abundancy in cerebral cortex, kidney, thyroid, and lymphoid tissues. Inside the cell, MLL is part of a stable multiprotein supercomplex, the majority of which are components of transcription complexes, including TFIID. The MLL multiprotein complex seems to remodel, acetylate, deacetylate, and methylate nucleosomes and/or free histones. MLL contains a SET domain characteristic for histone H3 lysine-4-specific methyltransferases. Oncogenic MLL fusion proteins appear to alter the methyltransferase activity of wild-type MLL.
Other Names:
Histone-lysine N-methyltransferase 2A, Lysine N-methyltransferase 2A, ALL-1, CXXC-type zinc finger protein 7, Myeloid/lymphoid or mixed-lineage leukemia, Myeloid/lymphoid or mixed-lineage leukemia protein 1, Trithorax-like protein, Zinc finger protein HRX, MLL cleavage product N320, N-terminal cleavage product of 320 kDa, p320, MLL cleavage product C180, C-terminal cleavage product of 180 kDa, p180, KMT2A, ALL1, CXXC7, HRX, HTRX, MLL, MLL1, TRX1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6182a was selected from the C-term region of human MLL1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: KMT2A
Gene ID: 4297
Primary Accession: Q03164
Other Accession: NP_005924
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Chromosome 11q23 translocations targeting mixed-lineage leukemia 1 (MLL) gene have been correlated with human acute leukemias, including lymphoid, myeloid, monoblastic and myelomonocytic varieties. More than 3 dozen genes that fuse to with MLL have been identified in various types of malignancies, including AF4, AF9, ENL, CBL, LARG, LPP, GMPS, and FBP17. The 431 kDa MLL protein exhibits greatest abundancy in cerebral cortex, kidney, thyroid, and lymphoid tissues. Inside the cell, MLL is part of a stable multiprotein supercomplex, the majority of which are components of transcription complexes, including TFIID. The MLL multiprotein complex seems to remodel, acetylate, deacetylate, and methylate nucleosomes and/or free histones. MLL contains a SET domain characteristic for histone H3 lysine-4-specific methyltransferases. Oncogenic MLL fusion proteins appear to alter the methyltransferase activity of wild-type MLL.
Other Names:
Histone-lysine N-methyltransferase 2A, Lysine N-methyltransferase 2A, ALL-1, CXXC-type zinc finger protein 7, Myeloid/lymphoid or mixed-lineage leukemia, Myeloid/lymphoid or mixed-lineage leukemia protein 1, Trithorax-like protein, Zinc finger protein HRX, MLL cleavage product N320, N-terminal cleavage product of 320 kDa, p320, MLL cleavage product C180, C-terminal cleavage product of 180 kDa, p180, KMT2A, ALL1, CXXC7, HRX, HTRX, MLL, MLL1, TRX1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6182a was selected from the C-term region of human MLL1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: KMT2A
Gene ID: 4297
Primary Accession: Q03164
Other Accession: NP_005924
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review